TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07402070: A Phase II Study Evaluating the Efficacy and Safety of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07402070 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07402070 Rescue Dossier →